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A B S T R A C T
Background: Calciﬁc aortic stenosis and coronary artery disease share common risk factors. In some of
the previous studies statins have been used to retard the progression of aortic stenosis, but the results
were inconsistent.
Methods: One hundred and ten patients of CAS above the age of 40 years have undergone clinical,
biochemical and echocardiographic evaluation. Coronary angiograms were done in 66% of them.
Results: Male to female ratio was 2:1. Patients of CAS with CAD showed higher prevalence of diabetes,
hypertension, dyslipidemia, smoking and family history of CAD. Prevalence of obesity and bicuspid
aortic valve by echocardiogram was high in those without CAD.
Conclusions: On comparison of prevalence of risk factor in those with and without associated CAD, there
was higher prevalence of diabetes (65% vs 30%), hypertension (52% vs 43%), dyslipidemia (69% vs 52%),
smoking (24% vs 18%) and family history of CAD (34% vs 16%) in those with associated CAD. The incidence
of obesity was higher in those without CAD (20% vs 30%). The difference observed in diabetes alone was
found to be statistically signiﬁcant.
 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Calciﬁc aortic stenosis (CAS) is the most common valve disorder
in the western world1 and is the most common indication for aortic
valve replacement (AVR) in the elderly.2 In general population,
1–2% of subjects have bicuspid aortic valve (BAV) which
predisposes to early development of aortic stenosis (AS).3 There
is growing experimental evidence suggesting that aortic valve (AV)
calciﬁcations is an active biological process with some similarities
to vascular atherosclerosis.4–7
Pomerance8 described calciﬁcation of AV cusps that was
preceded by lipid deposition similar to that seen in coronary
atherosclerosis. Both atherosclerosis and CAS were found to be
associated with familial hypercholesterolemia. Stewart et al.9 from
the Cardiovascular Health Study reported that independent risk
factors associated with CAS included elevated LDL cholesterol and
LP(a), hypertension, male gender, smoking and these risk factors* Corresponding author at: Apollo Hospitals, 21, Greams Lane, Chennai 600006,
India.
E-mail address: drismurthy@gmail.com (I. Sathyamurthy).
1 Present address: Department of Cardiology, Govt TD Medical College,
Alappuzha, Kerala, India.
http://dx.doi.org/10.1016/j.ihj.2016.04.007
0019-4832/ 2016 Cardiological Society of India. Published by Elsevier B.V. This is an
licenses/by-nc-nd/4.0/).were similar to those observed with coronary artery disease (CAD)
in the Framingham study. This new information opens up new
avenue that can be targeted with statins in the medical
management of CAS to prevent or retard the progression of
CAS.10,11 There is no data available regarding risk factor proﬁle in
patients with CAS in Indian literature. The aim of the present
prospective study was to evaluate the risk factors and compare the
risk factor proﬁle in patients of CAS with and without associated
CAD.
2. Material and methods
This prospective study was carried out at a tertiary hospital at
Chennai between January and December 2012. One hundred and
ten patients of CAS satisfying the inclusion criteria of age 40 years
were included in the study. Informed written consent was
obtained from all of them and ethics committee approval
was obtained as per mandatory hospital regulation. There were
74 males (67%) and 36 females (33%). Their ages ranged between
40 and 84 years (mean age 56.2 years). The age distribution was
shown in Table 1. The majority of patients were above the age of
60 years. Those with rheumatic heart disease, associated mitral
valve disease, those with more than mild aortic regurgitation, atrial open access article under the CC BY-NC-ND license (http://creativecommons.org/
Table 1
Sex distribution in different age groups.
Age group Male n (%) Female n (%) Total (n = 110)
40–49 years 8 (7.1%) 1 (0.9%) 9 (8%)
50–59 years 21 (19%) 9 (8%) 30 (27%)
60–69 years 29 (26%) 15 (14%) 44 (40%)
70–79 years 15 (14%) 10 (9%) 25 (23%)
80 years 1 (0.9%) 1 (0.9%) 2 (2%)
Table 3
Echocardiographic parameters in our study group.
Parameters Number of patients (n = 110) Percentage
Ejection fraction
55% 85 77.3%
45–54% 08 7.3%
30–44% 14 12.7%
<30% 03 2.7%
Aortic valve area (cm2)
<1.0 72 65.5%
1–1.5 38 34.5%
AV jet velocity (m/s)
<3 01 0.9%
3–4 15 13.6%
>4 94 85.5%
Mean gradient (mmHg)
<25 01 0.9%
25–40 09 8.2%
>40 100 90.9%
Mitral annular calciﬁcation 20 18.2%
Bicuspid Aortic valve 24 22%
Table 4
Prevalence of CAD in calciﬁc AS (n = 73).
Coronary angiogram Number Percentage RWMA by echo
Normal coronaries 44 60.3%
Single vessel disease 09 12.3%
Double vessel disease 10 13.7% 2
Triple vessel disease 10 13.7% 3
RWMA, regional wall motion abnormality.
Table 5
Prevalence of risk factors in calciﬁc AS patients with and without CAD.
Risk factor (%) Calciﬁc AS with
CAD n = 29 (40%)
Calciﬁc AS without
CAD n = 44 (60%)
P value
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creatinine more than 2 mg% were excluded from the study.
Data was recorded by taking detailed history, clinical examina-
tion and biochemical tests. The variables collected were pulse rate,
blood pressure, BMI and detailed cardiovascular system examina-
tion. BMI more than 30 was considered as obese. Biochemical
parameters were mainly to evaluate the risk factor proﬁle which
included routine hemogram, renal function tests, lipid proﬁle,
blood sugar levels, including glycosylated hemoglobin%. ECG, chest
X-ray PA view and 2D echocardiograms (Echo) were performed in
all of them. Risk factor proﬁles and their age groups were shown in
Table 2.
2.1. Echocardiography
Echo evaluation included AV jet velocity, AV area and
transaortic mean gradients. Echo evaluation also helped to detect
mitral valve disease, severity of aortic regurgitation and associated
mitral annular calciﬁcation. In addition echo evaluation revealed
associated regional wall motion abnormalities and left ventricle
ejection fraction (LVEF). Echo parameters were shown in Table 3.
2.2. Coronary angiography
It was performed in 73 patients (66%) who were subjected to
AVR. When the coronary anatomy revealed more than 50%
diameter stenosis they were labeled as signiﬁcant coronary
obstruction. Coronary artery involvement was shown in
Table 4. Subgroup comparative analysis of the risk factors was
done in those with and without associated CAD (Table 5).
The analysis was carried out using SPSS software version
11.0. All the categorical variables were expressed as percentages.
Comparisons between categorical variables were done using Chi
square test and Fisher’s exact test when the number of observa-
tions were small.
3. Results
In our study we found high incidence of CAS in males compared
to females. Regarding age distribution 65% of our CAS patientsTable 2
Distribution of atherosclerotic risk factors in different age groups.
Risk factors Age groups (n = 110)
40–49
years
(n = 9)
50–59
years
(n = 30)
60–69
years
(n = 44)
70–79
years
(n = 25)
80 years
(n = 2)
Diabetes mellitus 0 14 19 11 1
Systemic
hypertension
1 13 22 16 2
Dyslipidemia 3 15 29 13 1
Smoking 3 5 12 4 0
Obesity 2 7 13 5 0
Family history
of CAD
0 8 7 3 0
Tobacco chewing 0 0 1 0 0were above 60 years. Majority of those above the age of 50 years
had diabetes mellitus and hypertension. Our observations revealed
61 patients (55%) were dyslipidemic, 54 patients (49%) had
hypertension, 45 patients (41%) had diabetes mellitus, 27 patients
(25%) were obese (BMI more than 30), 24 patients (22%) were
smokers and only 1 patient gave history of tobacco chewing.
Family history of CAD was noted in 18 patients (16%) (Table 2). The
distribution of atherosclerotic risk factors did not show any
particular age preferences except that smoking was more common
above the age of 50 years.
3.1. Echocardiography (Table 3)
Out of 110 patients, 24 (22%) had BAV. 85 patients (77.5%) had
normal LVEF. Eight patients (7.3%) had mild LV dysfunction,Diabetes n (%)
Yes 19 (65) 13 (30) 0.00243
No 10 (35) 31 (70)
Hypertension
Yes 15 (52) 19 (43) 0.4740
No 14 (48) 25 (57)
Dyslipidemia
Yes 20 (69) 23 (52) 0.156
No 9 (31) 21 (48)
Smoking
Yes 7 (24) 8 (18) 0.53
No 22 (76) 36 (82)
Family history of CAD
Yes 10 (34) 7 (16) 0.06
No 19 (66) 37 (84)
Obesity
Yes 6 (20) 13 (30) 0.398
No 23 (80) 31 (70)
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(10%) showed regional wall motion abnormality suggestive of
associated CAD. In the present study we found 72 patients (65.5%)
had AVA 1 cm2 while 94 patients (85.5%) had aortic jet velocity
4 m/s and 100 patients (90.9%) showed mean gradients of
40 mmHg across AV. Associated mitral annular calciﬁcations
were observed in 20 patients (18.2%).
3.2. Coronary angiography
Among the 73 patients who have undergone coronary
angiography 29 patients (40%) had associated CAD. 9 patients
had single vessel disease, 10 patients had two vessel disease and
rest 10 patients had triple vessel disease (Table 4).
Subgroup analysis of risk factor in patients of CAS with and
without associated CAD revealed diabetes in 19 out of 29 (65%)
with CAD, hypertension in 15 patients (52%), dyslipidemia in
20 patients (69%) and smoking in 7 patients (24%). When CAS
patients with CAD compared to those without CAD none of the
variables were found to be statistically signiﬁcant except diabetes
(P value 0.00243).
4. Discussion
Several studies have documented strong association of
traditional risk factors with CAS as well as with coronary
atherosclerosis.10 The largest prospective population based study9
the cardiovascular health study included 5621 subjects above the
age of 65 years, reported a strong positive association between CAS
with atherosclerotic risk factors like age, male gender, smoking,
hypertension, elevated levels of LP(a) and LDL cholesterol.
Mean age in our study was 56.2 years. In the Monica/Kora
survey12 the mean age was 55 years while in SEAS study13 it was
67 years and in SALTIRE14 group it was 68 years. In the study by
Hachicha et al.15 the mean age was 69 and 73 years in normal ﬂow
and low ﬂow groups respectively. It is understandable that in the
Hachicha study, low ﬂow patients were elderly as majority of them
included had severe LV dysfunction. The age distribution in our
(Indian) patients is comparable to most of the previously reported
studies mentioned above.
In the present study, males versus females was 67%:33%,
showing a male preponderance. In the Monica/Kora study11 52%
were males, in SALTIRE14 group 70%, in SEAS study13 61.3% were
males. In the study reported by Hachicha et al.,15 revealed 61%
males in the normal ﬂow group and 49% in the paradoxical low
ﬂow group with an average 56% males. Ortlepp et al.,16 reported
male preponderance (55%) but in RAAVE study17 males were only
47%. Our study is in agreement with previously reported studies as
regards gender preponderance excepting the RAAVE study.
In our study 55% had dyslipidemia which is high compared to
other studies. In Kora/Monica study it was 31%, in SALTIRE study
10% in the statin group and only 6% in placebo group. In the study
by Ortlepp et al. it was 49% and Hachicha et al. reportedTable 6
Comparison of risk factors of calciﬁc aortic stenosis in different studies.
Study Kora/Monica12 SEAS11 SALTIRE14 O
Mean age 55 67 68 7
Male gender % 52 61.3 70 5
Dyslipidemia % 31 100 Statin 10%
Placebo 6%
4
Hypertension % 49.8 51 52 5
Diabetes % 3.7 – 5 2
Smoking % 25.8 55 22 4
Obesity % 45 – – dyslipidemia in more than 50% cases in both normal ﬂow and
low ﬂow groups. This makes a point to initiate statin therapy in
these patients. However the SEAS study13 which is the largest
randomized study to date failed to show any beneﬁt of Simvastatin
and Ezetimibe combination in reducing cardiovascular risk in
patients of CAS.
Hypertension was noted in around 50% of cases in the present
study. Even in SEAS study and Kora/Monica survey it was around
50% but the percentage of hypertensives was high in other studies,
SALTIRE (65%), Ortlepp (59%) and Hachicha et al. (70%). The high
percentage in Hachicha’s study could be due to inclusion of low
ﬂow, low gradient patients in whom associated hypertension can
result in double load over the left ventricular ejection. Essential
hypertension has been described as a classical risk factor for
progression of CAS.9 Optimal treatment of hypertension becomes a
major target for the management of CAS.
The percentage of diabetics (41%) was very high in our study
compared to Kora/Monica study (3.7%), SALTIRE study (5%),
Hachicha et al. (27%) while Ortlepp et al. reported diabetes in
only 20% of their cases. This can be explained due to high
prevalence of diabetes in our population and partly could be due to
less number of patients in our study.
Twenty ﬁve percent were obese (BMI  30) in our study,
whereas it was 33% in Hachicha study. In Kora/Monica study 45%
were obese and the high percentage of obese subjects in this study
can be explained on the basis that they used NIH consensus
development panel criteria (BMI  27.3 in men and 27.8 in
women).
In our study 22% were smokers and more or less similar
observations was noted in Kora/Monica study (25.8%), SEAS study
(20%) and in Ortlepp study smoking was reported in 41%. Family
history of CAD was reported in 28% by Ortlepp et al. while in our
study we observed only in 16% of our cases. Our observations of
risk factor proﬁle were compared with some of the major studies as
shown in Table 6.
Among 73 subjects who underwent coronary angiograms 40%
showed signiﬁcant CAD in our study. In the Ortlepp study it was
53% and in SALTIRE study it was 28%. In Hachicha study 60% had
associated CAD, a very high prevalence, which was due to
inclusion of low ﬂow low gradient AS patients. In the VA
cooperative study on valvular heart disease,18 429 (48%) out of
896 of AS patients had 50% stenosis of one or more coronary
arteries. In our study we did not perform coronary angiogram in
those below age of 50 years and also those who were low risk
candidates for CAD.
On comparison of prevalence of risk factor in those with and
without associated CAD, there was higher prevalence of diabetes
(65% vs 30%), hypertension (52% vs 43%), dyslipidemia (69% vs
52%), smoking (24% vs 18%) and family history of CAD (34% vs
16%) in those with associated CAD but the incidence of obesity
was higher in those without CAD (20% vs 30%). The difference
observed in diabetes alone was found statistically signiﬁcant
(Table 5).rtlepp et al.16 Hachicha et al.15 RAAVE17 Present study
0 70 73 56.2
5 55 47 63
9 49 50.4 55
9 59 63.6 50
0 27 32.2 41
1 – 3.3 22
– 32 – 25
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To our knowledge there was no previously reported studies
on CAS in Indian patients. Though this was a prospective study
the number of cases were less. Only two thirds of them have
undergone coronary angiograms. There was no long term follow up.
6. Conclusions
This is the ﬁrst Indian prospective study where CAS with
association of coronary risk factors was studied. Our study revealed
high prevalence of male gender, dyslipidemia, hypertension and
diabetes. The prevalence of diabetes was high in our study
compared to other published studies. It is worthwhile starting
statin therapy in them at early stages with a presumption of
retarding progression of CAS. Optimal control of co morbid risk
factors is also important.
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